Isolation of immunoresistant human glioma cell clones after selection with alloreactive cytotoxic T lymphocytes: Cytogenetic and molecular cytogenetic characterization

Cancer Genetics and Cytogenetics

Volumn 165, Issue 2, 2006, Pages 121-134

  Gomez, German G ^a   Varella Garcia, Marileila ^a   Kruse, Carol A ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b LA JOLLA INSTITUTE FOR MOLECULAR MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOIMMUNITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL ISOLATION; CELL SELECTION; CELL TYPE; CONTROLLED STUDY; CYTOGENETICS; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EXPERIMENTAL MODEL; FOLLOW UP; GENE MUTATION; GENETIC PROCEDURES; GENOME ANALYSIS; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOLOGICAL PROCEDURES; MOLECULAR CLONING; MOLECULAR GENETICS; PRIORITY JOURNAL; STRUCTURAL CHROMOSOME ABERRATION; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY;

BRAIN NEOPLASMS; CHROMOSOME BANDING; GLIOMA; HUMANS; IMMUNOTHERAPY; KARYOTYPING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33644760378     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2005.08.009     Document Type: Article

References (43)

1. Central Brain Tumor Registry of the United States (CBTRUS). Statistical report: primary brain tumors in the United States, 1995-1999. CBTRUS, 2002 [Available at: http://www.cbtrus.org/reports/reports.html ].
2. R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, M.J. Taphoorn, K. Belanger, A.A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R.C. Janzer, S.K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J.G. Cairncross, E. Eisenhauer, R.O. Mirimanoff, and European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
3. M.D. Prados, M.S. Berger, and C.B. Wilson Primary central nervous system tumors: advances in knowledge and treatment CA Cancer J Clin 48 1998 331 360
4. E.R. Laws Jr., and K. Thapar Brain tumors CA Cancer J Clin 43 1993 263 271
5. N. Virasch, and C.A. Kruse Strategies using the immune system for therapy of brain tumors Hematol Oncol Clin No Am 15 2001 1053 1071
6. D.B. Paul, and C.A. Kruse Immunologic approaches to therapy for brain tumors Curr Neurol Neurosci Rep 1 2001 238 244
7. C.A. Kruse, and D. Rubinstein Cytotoxic T-lymphocytes reactive to patient major histocompatibility complex proteins for therapy of brain tumors L.M. Liau D.P. Becker T.F. Cloughesy D.D. Bigner Brain tumor immunotherapy 2001 Humana Press Totowa, NJ 149 170
8. C.A. Kruse, L. Cepeda, B. Owens, S.D. Johnson, J. Stears, and K.O. Lillehei Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2 Cancer Immunol Immunother 45 1997 77 87
9. N.P. Restifo, F.M. Marincola, Y. Kawakami, J. Taubenberger, J.R. Yannelli, and S.A. Rosenberg Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy J Natl Cancer Inst 88 1996 100 108
10. S.A. Rosenberg, J.C. Yang, P.F. Robbins, J.R. Wunderlich, P. Hwu, R.M. Sherry, D.J. Schwartzentruber, S.L. Topalian, N.P. Restifo, A. Filie, R. Chang, and M.E. Dudley Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma J Immunother 26 2003 385 393
11. S.L. Topalian, A. Kasid, and S.A. Rosenberg Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes: possible mechanisms for immunotherapeutic failures J Immunol 144 1990 4487 4495
12. A.J. Papadopoulos, X. Han, A. Matossian-Rogers, and K.S. Raju Induction of immunocellular resistance to IL-2-activated lymphocytes within ovarian carcinoma cells Gyn Oncol 57 1995 388 394
13. L. Rivoltini, C. Gambacorti-Passerini, R. Supino, and G. Parmiani Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells: relevance to doxorubicin resistance Int J Cancer 43 1989 880 885
14. F. Ruiz-Cabello, T. Cabrera, M.A. Lopez-Nevot, and F. Garrido Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy Semin Cancer Biol 12 2002 15 24
15. P. Mukherjee, C.S. Madsen, A.R. Ginardi, T.L. Tinder, F. Jacobs, J. Parker, B. Agrawal, B.M. Longenecker, and S.J. Gendler Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer J Immunother 26 2003 47 62
16. C.L. Slingluff Jr., T.A. Colella, L. Thompson, D.D. Graham, J.C. Skipper, J. Caldwell, L. Brinckerhoff, D.J. Kittlesen, D.H. Deacon, C. Oei, N.L. Harthun, E.L. Huczko, D.F. Hunt, T.L. Darrow, and V.H. Engelhard Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens Cancer Immunol Immunother 48 2000 661 672
17. E. Fiore, C. Fusco, P. Romero, and I. Stamenkovic Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity Oncogene 21 2002 5213 5223
18. P.R. Walker, P. Saas, and P.Y. Dietrich Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back J Immunol 158 1997 4521 4524
19. B.R. Gastman, Y. Atarashi, T.E. Reichert, T. Saito, L. Balkir, H. Rabinowich, and T.L. Whiteside Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes Cancer Res 59 1999 5356 5364
20. C.N. Baxevanis, G.J. Reclos, A.D. Gritzapis, G.V. Dedousis, I. Missitzis, and M. Papamichail Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer Cancer 72 1993 491 501
21. H. Fakhrai, O. Dorigo, D.L. Shawler, H. Lin, D. Mercola, K.L. Black, I. Royston, and R.E. Sobol Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy Proc Natl Acad Sci U S A 93 1996 2909 2914
22. R.M. Pitti, S.A. Marsters, D.A. Lawrence, M. Roy, F.C. Kischkel, P. Dowd, A. Huang, C.J. Donahue, S.W. Sherwood, D.T. Baldwin, P.J. Godowski, W.I. Wood, A.L. Gurney, K.J. Hillan, R.L. Cohen, A.D. Goddard, D. Botstein, and A. Ashkenazi Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer Nature 396 1998 699 703
23. P. Kamarajan, N.K. Sun, and C.C. Chao Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling Biochem J 376 2003 253 260
24. J.P. Medema, J. de Jong, T. van Hall, C.J. Melief, and R. Offringa Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein J Exp Med 190 1999 1033 1038
25. J.P. Medema, J. de Jong, L.T.C. Peltenburg, E.M. Verdegaal, A. Gorter, S.A. Bres, K.L. Franken, M. Hahne, J.P. Albar, C.J. Melief, and R. Offringa Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors Proc Natl Acad Sci U S A 98 2001 11515 11520
26. G.G. Gomez, and C.A. Kruse Isolation and culture of human brain tumor cells Methods Mol Med 88 2004 101 109
27. J.J. Hessling, S.E. Miller, and N.L. Levy A direct comparison of procedures for the detection of mycoplasma in tissue culture J Immunol Methods 38 1980 315 324
28. C.A. Kruse, D.H. Mitchell, B.K. Kleinschmidt-DeMasters, W.A. Franklin, H.G. Morse, E.B. Spector, and K.O. Lillehei Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses In Vitro Cell Dev Biol 28A 1992 609 614
29. C.A. Kruse, and L.T. Beck Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours Biotechnol Appl Biochem 25 1997 197 205
30. R.T. Carson, and D.A.A. Vignali Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay J Immunol Methods 227 1999 41 52
31. G.G. Gomez, S.B. Read, L.E. Gerschenson, D. Santoli, A. Zweifach, and C.A. Kruse Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors Neuro-Oncol 6 2004 83 95
32. A. van Bokhoven, A. Caires, M.D. Maria, A.P. Schulte, M.S. Lucia, S.K. Nordeen, G.J. Miller, and M. Varella-Garcia Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines Prostate 57 2003 226 244
33. ISCN 1995: an international system for human cytogenetic nomenclature (1995) F. Mitelman 1995 S. Karger Basel
34. C.A. Kruse, M. Varella-Garcia, B.K. Kleinschmidt-Demasters, G.C. Owens, E.B. Spector, H. Fakhrai, E. Savelieva, and B.C. Liang Receptor expression, cytogenetic, and molecular analysis of six continuous human glioma cell lines In Vitro Cell Dev Biol Anim 34 1998 455 462
35. A. Bakir, F. Gezen, O. Yildiz, A. Ayhan, S. Kahraman, C.A. Kruse, M. Varella-Garcia, F. Yildiz, and A. Kubar Establishment and characterization of a human glioblastoma multiforme cell line Cancer Genet Cytogenet 103 1998 46 51
36. R.A. Gjerset, H. Fakhrai, D.L. Shawler, S. Turla, O. Dorigo, A. Grover-Bardwick, D. Mercola, S.F. Wen, H. Collins, H. Lin, M. Varella-Garcia, C.A. Kruse, I. Royston, and R.E. Sobol Characterization of a new human glioblastoma cell line that expresses mutant p53 and lacks activation of the PDGF pathway In Vitro Cell Dev Biol Anim 31 1995 207 214
37. E. Van Meir, Y. Sawamura, A.C. Diserens, M.F. Hamou, and N. de Tribolet Human glioblastoma cells release interleukin 6 in vivo and in vitro Cancer Res 50 1990 6683 6688
38. D.J. Brat, A.C. Bellail, and E.G. Van Meir The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis Neuro-oncol 7 2005 122 133
39. J.R. Sawyer, C.M. Swanson, W.M. Chadduck, and G.J. Roloson Evolution of tumor chromosome abnormalities after therapy in a pediatric astrocytoma Cancer Genet Cytogenet 53 1991 119 123
40. Y.S. Lai, D.A. Ramsay, D.R. Macdonald, and R.F. Del Maestro Therapy-related chromosomal changes and cytogenetic heterogeneity in human gliomas J Neurooncol 32 1997 7 17
41. G.G. Gomez, and C.A. Kruse Cytogenetic and DNA microarray analysis of human glioma cell models resistant to alloreactive cytotoxic T lymphocytes Proc Am Assoc Cancer Res 46 2005 abst 4254
42. R. Hofer-Warbinek, J.A. Schmid, H. Mayer, G. Winsauer, L. Orel, B. Mueller, Ch. Wiesner, B.R. Binder, and R. de Martin A highly conserved proapoptotic gene, IKIP, located next to the APAF1 gene locus, is regulated by p53 Cell Death Differ 11 2004 1317 1325
43. A. Fujimoto, H. Takeuchi, B. Taback, E.C. Hsueh, D. Elashoff, D.L. Morton, and D.S. Hoon Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma Cancer Res 64 2004 2245 2250